Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 156


Factors determining antibody distribution in tumors.

Thurber GM, Schmidt MM, Wittrup KD.

Trends Pharmacol Sci. 2008 Feb;29(2):57-61. doi: 10.1016/ Epub 2008 Jan 7.


Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen.

Tang Y, Lou J, Alpaugh RK, Robinson MK, Marks JD, Weiner LM.

J Immunol. 2007 Sep 1;179(5):2815-23.


Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice.

Garg A, Balthasar JP.

J Pharmacokinet Pharmacodyn. 2007 Oct;34(5):687-709. Epub 2007 Jul 18.


Theoretic criteria for antibody penetration into solid tumors and micrometastases.

Thurber GM, Zajic SC, Wittrup KD.

J Nucl Med. 2007 Jun;48(6):995-9. Epub 2007 May 15.


Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin.

Müller D, Karle A, Meissburger B, Höfig I, Stork R, Kontermann RE.

J Biol Chem. 2007 Apr 27;282(17):12650-60. Epub 2007 Mar 8.


Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: optimal pharmacokinetics for therapy.

Kenanova V, Olafsen T, Williams LE, Ruel NH, Longmate J, Yazaki PJ, Shively JE, Colcher D, Raubitschek AA, Wu AM.

Cancer Res. 2007 Jan 15;67(2):718-26.


Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent.

Dennis MS, Jin H, Dugger D, Yang R, McFarland L, Ogasawara A, Williams S, Cole MJ, Ross S, Schwall R.

Cancer Res. 2007 Jan 1;67(1):254-61.


Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and tumor cell motility and invasiveness.

Galaup A, Cazes A, Le Jan S, Philippe J, Connault E, Le Coz E, Mekid H, Mir LM, Opolon P, Corvol P, Monnot C, Germain S.

Proc Natl Acad Sci U S A. 2006 Dec 5;103(49):18721-6. Epub 2006 Nov 27.


PEGylation and multimerization of the anti-p185HER-2 single chain Fv fragment 4D5: effects on tumor targeting.

Kubetzko S, Balic E, Waibel R, Zangemeister-Wittke U, Plückthun A.

J Biol Chem. 2006 Nov 17;281(46):35186-201. Epub 2006 Sep 8.


Radiation-induced bystander and other non-targeted effects: novel intervention points in cancer therapy?

Mothersill C, Seymour C.

Curr Cancer Drug Targets. 2006 Aug;6(5):447-54. Review.


Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action.

Lammerts van Bueren JJ, Bleeker WK, Bøgh HO, Houtkamp M, Schuurman J, van de Winkel JG, Parren PW.

Cancer Res. 2006 Aug 1;66(15):7630-8.


Drug penetration in solid tumours.

Minchinton AI, Tannock IF.

Nat Rev Cancer. 2006 Aug;6(8):583-92. Review.


A two-tiered physiologically based model for dually labeled single-chain Fv-Fc antibody fragments.

Ferl GZ, Kenanova V, Wu AM, DiStefano JJ 3rd.

Mol Cancer Ther. 2006 Jun;5(6):1550-8.


The pharmacokinetics of an albumin-binding Fab (AB.Fab) can be modulated as a function of affinity for albumin.

Nguyen A, Reyes AE 2nd, Zhang M, McDonald P, Wong WL, Damico LA, Dennis MS.

Protein Eng Des Sel. 2006 Jul;19(7):291-7. Epub 2006 Apr 18.


A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies.

Lin Y, Pagel JM, Axworthy D, Pantelias A, Hedin N, Press OW.

Cancer Res. 2006 Apr 1;66(7):3884-92. Erratum in: Cancer Res. 2007 Feb 1;67(3):1405.


Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers.

Dreher MR, Liu W, Michelich CR, Dewhirst MW, Yuan F, Chilkoti A.

J Natl Cancer Inst. 2006 Mar 1;98(5):335-44.


Target-mediated drug disposition and dynamics.

Mager DE.

Biochem Pharmacol. 2006 Jun 28;72(1):1-10. Epub 2006 Feb 15. Review.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk